Summary

  • ~20% patients diagnosed with HR+, HER2- early breast cancer (EBC) may experience disease recurrence/distant relapse in the first 10 years 
  • Risk of recurrence is higher for those with high risk clinical and/or pathological features, especially during the first few years on adjuvant endocrine therapy (ET) 
  • Novel treatments are needed to prevent early recurrences and distant metastases

Is there a place in Early Breast Cancer for a CDK4 & 6 inhibitor currently approved for HR+, HER2- advanced breast cancer in combination with ET ?

Highlights

  • 1

    Abemaciclib combined with ET showed a statistically significant improvement in IDFS in patients with high risk HR+, HER2- EBC

  • 2

    Results indicate the prevention of early recurrence and a reduction in the risk of distant recurrence (metastatic disease) by a clinically meaningful 28.3%

  • 3

    Safety was consistent with the known profile of abemaciclib

Comments (0)